MetaCap

CNS Pharmaceuticals (CNSP) vs Pulmatrix (PULM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CNS Pharmaceuticals is the larger company by market cap ($5.3 million vs $4.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNSP-34.44%PULM-14.77%
+8%-21%-49%
Oct 7, 20261 yearNov 20, 2026
CNSP-33.46%PULM-13.01%
+4%-22%-48%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNSP versus PULM key metrics
MetricCNSPPULM
Share price$3.56$1.27
Market cap$5.25M$4.64M
1-day change-12.75%-10.56%
EPS (TTM)$-11.80$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-15.85M$-5.16M
52-week high$10.54$4.94
52-week low$1.90$1.06
Distance from 52-week high-66.22%-74.29%
Analyst consensusnone—
Avg. price target upside+180.90%—
Average volume9.30K35.45K
Shares outstanding1.48M3.65M
Employees82
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About CNS Pharmaceuticals

CNSP stock →

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Pulmatrix

PULM stock →

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

CNSP vs PULM FAQ

Which is bigger, CNS Pharmaceuticals or Pulmatrix?

CNS Pharmaceuticals (CNSP) is larger, with a market capitalization of $5.25M compared with $4.64M for Pulmatrix (PULM).

Are CNS Pharmaceuticals and Pulmatrix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons